Perrigo’s 10.8% Yield vs. 18% Short Interest: The Conflict

Forward-Looking Analysis

Perrigo (PRGO) enters the 2026Q2 earnings cycle with a consensus analyst rating of "Hold," reflecting a cautious market sentiment. The average price target stands at $19.33, implying significant upside potential from the current trading level of approximately $10.60, despite the company currently reporting negative earnings. Analyst coverage is sparse, with only two research reports issued in the past 90 days, comprising one buy, four hold, and one sell rating.

Looking forward, earnings are projected to grow by 13.74% over the next year, moving from $2.11 to $2.40 per share. However, the company's current Price-to-Earnings ratio is negative (-0.81) due to recent losses, rendering traditional P/E comparisons invalid against positive-earnings peers. Valuation metrics present a mixed picture: the PEG Ratio of 1.27 suggests potential overvaluation relative to growth, while the Price-to-Book ratio of 0.50 indicates the stock may be undervalued concerning its asset base.

Market sentiment is further complicated by high short interest, with 17.83% of the float sold short and a days-to-cover ratio of 4.67. Short interest has surged 39.80% recently, signaling decreasing investor confidence. Conversely, the dividend profile remains strong, with a 10.82% yield placing it in the top 25% of dividend payers, supported by a sustainable payout ratio of 48.33% based on next year's earnings estimates. Institutional ownership remains high at 95.91%, suggesting trust from major funds despite retail and short-seller skepticism. The overall financial outlook balances expected earnings recovery against current valuation ambiguities and heightened short-term bearish pressure.

Historical Performance Review

Perrigo’s 2026Q1 results demonstrated significant financial strain, characterized by a 7.2% year-over-year revenue decline to $969.20 million. The company reported a substantial net loss of $398.60 million, resulting in an EPS of -$2.87. Despite the top-line contraction, the gross profit stood at $325.50 million. These figures highlight a challenging period for the healthcare supplier, marked by negative earnings per share and declining revenues, setting a difficult baseline for the upcoming Q2 performance review and raising questions about near-term profitability restoration.

Additional News

Perrigo recently reinforced its corporate governance structure by strengthening its board with the appointment of two new independent directors on June 30, 2026. Concurrently, the company reinstated its executive severance policy amid an ongoing CEO transition, signaling administrative adjustments to leadership stability. Financially, the stock has underperformed significantly this year, dropping 23.9% from its start-of-year price of $13.92 to trade near $10.60. In contrast to recent volatility, insider trading activity has been neutral, with no insider buys or sales recorded in the past three months. The company continues to operate through key subsidiaries, including HRA Pharma and Omega Pharma, maintaining its global footprint in consumer health and generic pharmaceuticals.

Summary & Outlook

Perrigo’s financial health is currently fragile, evidenced by negative earnings and declining Q1 revenues, though its strong dividend yield offers some investor appeal. Growth catalysts include an expected 13.74% earnings growth rate and a potentially undervalued asset base indicated by a low P/B ratio. However, risks are elevated by high short interest and sparse analyst coverage. The stance on future prospects is cautiously neutral; while valuation metrics suggest potential upside, the company must overcome recent operational losses and negative sentiment to realize this growth. Investors should monitor Q2 revenue stability and margin improvement as critical indicators for reversing the current bearish trend.